Intercept Pharma (ICPT) Tops Q2 EPS by 21c; Offers FY22 Revenue Guidance

August 3, 2022 7:17 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Intercept Pharma (NASDAQ: ICPT) reported Q2 EPS of ($0.25), $0.21 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $71.76 million versus the consensus estimate of $95.98 million.


Intercept Pharma sees FY2022 revenue of $325-345 million, versus the consensus of $386.2 million.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities